Azathioprine for Connective Tissue Disease-Associated Interstitial Lung Disease
Author:
Publisher
S. Karger AG
Subject
Pulmonary and Respiratory Medicine
Reference23 articles.
1. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al.; Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007 Nov;176(10):1026–34.
2. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al.; Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 Sep;4(9):708–19.
3. Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al.; SENSCIS Trial Investigators. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019 Jun;380(26):2518–28.
4. Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016 Jun;387(10038):2630–40.
5. Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials. 2017 Jun;18(1):275.
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Efficacy and safety of pharmacological treatments for autoimmune disease-associated interstitial lung disease: A systematic review and network meta-analysis;Seminars in Arthritis and Rheumatism;2024-10
2. Interstitial pneumonia with autoimmune features: Aiming to define, refine, and treat;Revista Colombiana de Reumatología (English Edition);2024-04
3. Potential Rheumatoid Arthritis-Associated Interstitial Lung Disease Treatment and Computational Approach for Future Drug Development;International Journal of Molecular Sciences;2024-02-26
4. Progressive pulmonary fibrosis: where are we now?;Tuberculosis and Respiratory Diseases;2023-12-18
5. Interstitial pneumonia with autoimmune features: Aiming to define, refine, and treat;Revista Colombiana de Reumatología;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3